McKesson Corporation (MCK, Financial), a leading pharmaceutical giant, saw its shares rise by 7.2% in premarket trading, reaching $588.9. The company's performance in the second quarter of fiscal 2025 exceeded market expectations, with adjusted earnings per share reported at $7.07, surpassing the forecasted $6.88. Revenue also impressed, coming in at $93.7 billion, which was significantly higher than the anticipated $89.33 billion.
In a display of confidence in its continued robust performance, McKesson raised its earnings outlook for fiscal year 2025. Furthermore, the company increased its share repurchase goal for the entire year from $2.8 billion to $3.2 billion.
